 Completed an initial public offering with net proceeds, including the exercise of the underwriters option in full, of approximately 48.4 million in May 2021 - - - Expanded the management team to support initiation of atacicept clinical development program - - - Initiated Phase 2b ORIGIN clinical trial of atacicept in patients with IgA nephropathy IgAN 